Since our inception in Oxford in 2015, Panacea has been pivotal in the formation of over 300 companies, propelling our top 55 to a combined valuation of approximately £1Bn. Our unique blend of comprehensive R&D, commercialisation support, and essential funding transforms promising ideas into viable, successful enterprises.
Exclusive Support and Investment Opportunities
We’re committed to advancing health-related innovations, from early-stage ideas to ready-for-market products. Our equity-free programs offer significant benefits: up to £100k in prizes, complimentary lab space, and wide-ranging support in scientific, clinical, financial, and legal aspects. The standout companies gain priority access to pre-seed and seed investments through Panacea Ventures.
Distinguishing Panacea Stars is our robust network of over 200 C-suite mentors from leading entities like AstraZeneca, GSK, AbbVie, Novo Nordisk, IBM, Bio-Rad, Taylor Wessing, J A Kemp, and McKinsey & Co. These mentors, poised to join company boards, along with support from esteemed funding bodies such as Cancer Research UK and the British Heart Foundation, significantly amplify our participants’ development and success.
Join Our Develop Spring/Summer 2024 Cohort!
| Application deadline |
22/03/2024 |
| Event type |
Programme |
| Application required? |
Apply Here |
